Pacific Biosciences of California Inc (PACB)
Drugs • Health Care
July 28, 2026 Pacific Biosciences to Showcase Innovations at Canaccord Genuity Annual Growth Conference Pacific Biosciences will showcase its innovative sequencing technologies at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event will include a live webcast, allowing stakeholders to engage with the company’s advancements in genetic research.
July 15, 2026 Pacific Biosciences Sets Date for Second Quarter 2026 Financial Results Pacific Biosciences will report its Q2 2026 financial results on August 5, 2026, with a live conference call for investors. The company focuses on advancing genomic science with innovative sequencing technologies.
May 26, 2026 PacBio Unveils Groundbreaking SPRQ-Nx Chemistry for Affordable HiFi Genomes Pacific Biosciences has unveiled SPRQ-Nx chemistry, reducing HiFi genome sequencing costs below $300. Enhanced by AI integration, this innovation aims to improve accuracy and efficiency, crucial for large-scale genomic research.
May 21, 2026 PacBio to Showcase Innovations at Jefferies Global Healthcare Conference Pacific Biosciences will participate in the Jefferies Global Healthcare Conference, featuring a fireside chat that discusses their innovations in sequencing technology. The event will provide valuable insights into the company's strategic direction and its implications for the life sciences sector.
May 08, 2026 Pacific Biosciences of California Inc. Q1 2026 Financial Report: A Promising Shift Pacific Biosciences of California Inc. reported a promising Q1 2026 financial turnaround, with increased revenue from consumables despite challenges in instrument sales. The company aims to enhance its market position through strategic initiatives and innovation in genomic sequencing.
May 07, 2026 Pacific Biosciences of California Inc. Reports First Quarter 2026 Financial Results Pacific Biosciences reported stable Q1 2026 results, with $37.2M in revenue and a focus on key collaborations. Despite challenges in instrument sales, the company shows growth potential through strategic partnerships and improved financial health.
April 21, 2026 PacBio and Lucid Genomics Forge Strategic Alliance for Enhanced Genomic Insights PacBio and Lucid Genomics have formed a strategic alliance to enhance tertiary analysis for long-read sequencing. This collaboration aims to streamline genomic data interpretation, enabling researchers to derive actionable insights more efficiently.
April 16, 2026 PacBio Scheduled to Release First Quarter 2026 Financial Results Pacific Biosciences will announce its Q1 2026 financial results on May 7, 2026, during a conference call at 4:30 p.m. ET. Stakeholders are invited to join the discussion for insights into the company's performance and future strategies.
April 15, 2026 PacBio and Covaris Unveil Revolutionary Workflow for HiFi Long-Read Sequencing of FFPE Tumor Samples PacBio and Covaris have launched an innovative workflow for HiFi long-read sequencing of FFPE tumor samples, addressing challenges in DNA extraction and sequencing quality. This collaboration promises to unlock valuable insights from archived samples, significantly advancing cancer research.
March 18, 2026 Pacific Biosciences Partners with Basecamp Research for Groundbreaking Trillion Gene Atlas Initiative Pacific Biosciences partners with Basecamp Research to launch the Trillion Gene Atlas, aiming to create the largest metagenomic dataset using advanced HiFi sequencing technology. This collaboration seeks to enhance AI models for biological design, providing crucial insights into genetic diversity and therapeutic innovation.
March 05, 2026 PacBio Welcomes Dr. Chris Gibson to Its Board of Directors Pacific Biosciences has appointed Dr. Chris Gibson to its Board of Directors, enhancing its leadership in AI and biotechnology. Dr. Gibson's expertise will support PacBio's vision of integrating high-quality sequencing with advanced analytics to advance healthcare.
February 25, 2026 Pacific Biosciences of California Inc. Releases 2025 Annual Report: Financial Performance and Strategic Outlook Pacific Biosciences of California Inc. (PacBio) released its 2025 Annual Report, showcasing revenue growth but significant net losses. The report outlines strategic initiatives aimed at improving performance in the genomic sequencing market, despite challenges from market dynamics.
February 24, 2026 PacBio Partners with DNAstack to Advance Rare Disease Research PacBio has partnered with DNAstack to create the first global federated dataset of HiFi whole genome sequencing data aimed at improving rare disease research. This initiative enables secure data sharing among nearly 30 institutions worldwide, enhancing the accuracy of genomic insights while maintaining privacy.
February 18, 2026 Pacific Biosciences to Showcase Innovations at TD Cowen 46th Annual Health Care Conference Pacific Biosciences will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, highlighting their sequencing technologies. Investors can tune in to a live webcast to gain insights into the company's advancements in genomics and research applications.
February 12, 2026 Pacific Biosciences Partners with iHope to Enhance Genomic Sequencing for Rare Diseases Pacific Biosciences collaborates with the iHope Initiative to integrate advanced sequencing technology to enhance diagnostic capabilities for rare diseases. This partnership aims to improve genomic insights, supporting families facing diagnostic challenges and promoting precision medicine.
February 12, 2026 Pacific Biosciences Reports Strong Q4 and Full Year 2025 Financial Results Pacific Biosciences reported a 14% revenue increase for Q4 2025, driven by strong consumables sales. Despite a GAAP net loss, the company is optimistic about its future growth with new innovations and partnerships in genomic sequencing.
February 02, 2026 PacBio Completes Strategic Sale of Short-Read Sequencing Assets Pacific Biosciences has successfully sold its short-read sequencing assets to Illumina for $48.1 million, allowing the company to concentrate on long-read sequencing innovations. This strategic decision aims to strengthen its balance sheet and accelerate the development of new technologies like SPRQ-Nx.
January 27, 2026 PacBio Set to Reveal 2025 Financial Results: A Look Ahead PacBio will announce its 2025 financial results on February 12, 2026, during a conference call. This event is crucial for investors seeking insights into the company's performance and future direction in biotechnology.
January 12, 2026 PacBio Teams Up with n-Lorem Foundation and EspeRare to Revolutionize Rare Disease Therapies PacBio has partnered with the n-Lorem Foundation and EspeRare to enhance therapies for ultra-rare diseases using advanced long-read sequencing technology. This collaboration aims to streamline ASO therapy development, providing personalized treatments for patients with rare genetic disorders.
January 12, 2026 PacBio HiFi Sequencing: A New Hope in Investigating Sudden Unexplained Death in Childhood Pacific Biosciences partners with UW Medicine and Seattle Children’s Hospital to use HiFi sequencing in investigating Sudden Unexplained Death in Childhood (SUDC). This initiative aims to enhance diagnostic accuracy and provide vital insights into genetic factors affecting affected families.
January 12, 2026 Pacific Biosciences Reports Strong Preliminary Revenue Growth for Q4 and Full Year 2025 Pacific Biosciences reported a 14% revenue increase in Q4 2025, totaling approximately $44.6 million, and a 4% annual growth to $160 million. The company’s strong performance in consumables and new system placements positions it well for future growth in genomic sequencing.
January 08, 2026 PacBio Unveils Revolutionary CiFi Method for Chromosome-Scale Genome Assemblies PacBio has introduced CiFi, a revolutionary technique that combines chromatin conformation capture with HiFi sequencing for chromosome-scale genome assemblies. This method enhances mapping capabilities, especially in complex genomic regions, and is effective even with low sample inputs. It promises to simplify genomic projects while delivering high-quality results.
December 30, 2025 Pacific Biosciences Set to Showcase Innovations at J.P. Morgan Healthcare Conference Pacific Biosciences will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company will showcase its advanced sequencing technologies and provide a live webcast for remote viewers, emphasizing its commitment to research in genetics.
November 28, 2025 Pacific Biosciences to Showcase Innovations at Piper Sandler Healthcare Conference Pacific Biosciences will participate in the Piper Sandler Healthcare Conference on December 3, 2025, showcasing its innovative sequencing solutions. The fireside chat will provide insights into the company's strategic direction and future technologies, emphasizing its role in advancing genomic research.
November 13, 2025 Pacific Biosciences to Engage Investors at Key Conferences Pacific Biosciences is set to participate in major investor conferences in November 2025, including the Wolfe Research, Jefferies, and Stephens events. Management will showcase their advanced sequencing technologies and engage directly with investors through fireside chats and one-on-one meetings, emphasizing their commitment to innovation in the life sciences sector.
November 06, 2025 Pacific Biosciences of California Inc. Reports Q3 2025 Results: A Mixed Bag of Opportunities and Challenges Pacific Biosciences of California Inc. reported mixed results for Q3 2025, with total revenue declining but increased consumables sales. Despite significant operational losses and restructuring, the company focuses on strategic initiatives to improve financial health.
November 05, 2025 Pacific Biosciences Reports Third Quarter 2025 Financial Results Pacific Biosciences reported mixed Q3 2025 results with total revenue declining to $38.4 million. However, improvements in gross margin and reduced operating expenses indicate operational efficiency. Key innovations, including new sequencing technologies, underline the company's commitment to growth.
November 05, 2025 PacBio's HiFi Solves Consortium Achieves Milestone in Clinical Genomics PacBio's HiFi Solves Consortium has published a pivotal preprint demonstrating the effectiveness of HiFi sequencing in identifying pathogenic variants in clinical genomics. The study highlights the technology's superior accuracy and potential to streamline diagnostics, marking a significant advancement in genomic medicine.
November 04, 2025 PacBio Supports Berry Genomics in Achieving Groundbreaking Regulatory Approval in China PacBio's Sequel II CNDx system has received Class III Medical Device Registration approval from China's NMPA, marking a pivotal advancement in genomic testing. This system enhances the detection of complex genetic disorders, promising improved clinical outcomes and positioning China as a leader in clinical genomics.
October 22, 2025 PacBio Set to Unveil Third Quarter 2025 Financial Results Pacific Biosciences will announce their Q3 2025 financial results on November 5, 2025, during a live earnings call. Investors can expect insights on revenue, profit margins, and updates on their advanced sequencing technologies.
October 14, 2025 PacBio Unveils Revolutionary Advances in Genome Sequencing Technology Pacific Biosciences has unveiled its new SPRQ-Nx sequencing chemistry, reducing costs by 40% and enhancing multiomic capabilities. The updates to Revio and Vega platforms aim to make high-fidelity sequencing accessible for diverse genomic research applications.
October 13, 2025 PacBio's HiFi Technology Chosen for South Korea's National Pangenome Project PacBio's HiFi sequencing technology has been selected for South Korea's National Pangenome Project, aiming to create a comprehensive genetic reference for the Korean population. This initiative will enhance understanding of genetic diversity and enable precision medicine advancements.
October 08, 2025 PacBio Collaborates with National Institute on Aging to Explore Genetic Clues to Longevity PacBio and the National Institute on Aging have launched a partnership to study the genetic basis of longevity through the Long Life Family Study. Utilizing PacBio's HiFi sequencing technology, the study aims to identify structural variants linked to healthy aging in a large cohort of participants. This groundbreaking research could revolutionize our understanding of aging and lead to breakthroughs in precision medicine.
October 07, 2025 PacBio Expands Partnership with seqWell: A Leap Forward in Genomic Research PacBio has expanded its partnership with seqWell to enhance genomic research with the LongPlex™ Multiplexing Kit, streamlining sample preparation for high-quality data. This innovative kit allows simultaneous DNA fragmentation and indexing, enabling large-scale studies and greater efficiency in genomic workflows.
September 22, 2025 Pacific Biosciences Enters High-Throughput Carrier Screening Market with Innovative Solutions Pacific Biosciences has entered the high-throughput carrier screening market with its PureTarget product line, enhancing genetic testing efficiency. The new solutions aim to streamline workflows and improve access to comprehensive carrier screening, addressing the growing demand for genetic testing in healthcare.
August 07, 2025 Pacific Biosciences Reports Q2 2025 Results: Navigating Challenges and Opportunities Pacific Biosciences reported a 10% revenue increase to $77 million in Q2 2025, driven by consumable sales and the launch of the Vega platform. However, significant operational expenses and restructuring challenges impacted profitability. The company remains focused on innovation and market expansion.
May 12, 2025 Pacific Biosciences of California Inc. Reports Challenging Q1 2025 Financials Pacific Biosciences of California Inc. (PacBio) reports a 4% decline in revenue for Q1 2025, with substantial losses attributed to operational challenges and restructuring. Despite these setbacks, the company is focused on strategic initiatives to enhance growth and market reach.
March 27, 2025 Jim Gibson Appointed as Chief Financial Officer of Pacific Biosciences Jim Gibson has been appointed CFO of Pacific Biosciences, effective March 31, 2025. With over 30 years of experience in tech, he aims to enhance financial strategy and operational growth in genomics.
March 17, 2025 Pacific Biosciences of California Inc. Reports Challenging Year in 2024 Annual Financial Review Pacific Biosciences of California Inc. (PacBio) reported a challenging 2024, with a 23% decline in revenue and significant operational losses. Despite a rise in consumable sales, the company faces strategic hurdles and legal challenges that could impact its future growth.
March 17, 2025 Pacific Biosciences Unveils Breakthrough in Genomic Analysis with HiFi Sequencing Pacific Biosciences has unveiled a groundbreaking HiFi sequencing method, combined with the Paraphase tool, to accurately analyze complex genomic regions. This advancement enables the detection of previously undetected variants linked to significant health conditions, marking a pivotal moment in genomics.
February 19, 2025 PacBio to Showcase Innovations at TD Cowen's 45th Annual Health Care Conference Pacific Biosciences will showcase its latest genomic innovations at the TD Cowen Health Care Conference on March 4, 2025. The event highlights their commitment to advancing sequencing technology for research applications. A live webcast will be available for those unable to attend.
February 14, 2025 Pacific Biosciences of California Inc. Expands Workforce with Strategic Stock Incentives Pacific Biosciences has announced the grant of stock options and restricted stock units to a new employee as part of its strategy to attract top talent. This move aligns with Nasdaq rules and emphasizes the company's commitment to innovation in genomic research. The incentives include a significant vesting schedule to encourage long-term employee engagement.
February 13, 2025 Pacific Biosciences Reports Q4 and Fiscal Year 2024 Financial Results Pacific Biosciences reported a challenging Q4 2024, with a 33% revenue decline but a notable turnaround in net income due to debt restructuring gains. The company is focusing on strategic product launches and cost management for future growth.
January 28, 2025 SWOT Analysis of Pacific Biosciences of California Inc. in 2025 This article provides a comprehensive SWOT analysis of Pacific Biosciences of California Inc. for 2025, highlighting its technological strengths, ongoing challenges, and growth opportunities in the genomics sector. The analysis reveals how PacBio can leverage its advantages while addressing competition and financial hurdles.
November 12, 2024 Pacific Biosciences of California Inc.: 2024 Q3 Financial Report Highlights Pacific Biosciences of California Inc. reported a significant decline in revenue and increased operational losses in Q3 2024. The company is pursuing strategic initiatives and product development to enhance growth and recover market confidence.
August 09, 2024 Pacific Biosciences of California Inc. Reports Disappointing Q2 2024 Financial Results Pacific Biosciences of California Inc. reported a significant decline in revenue and increased operational losses for Q2 2024. Despite growth in consumables sales, the overall financial health of the company has worsened, prompting restructuring efforts to improve efficiency and navigate a challenging market landscape.
May 09, 2024 Pacific Biosciences of California Inc. Reports Q1 2024 Financial Results Pacific Biosciences reported mixed Q1 2024 financial results with a slight revenue decline to $38.8 million, but improved gross profit margins and reduced operational losses. The company is implementing strategic measures to enhance efficiency and reduce expenses while advancing its genomic sequencing technology.